Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1867386 | 0.83 | BCL2L1 (0.50) | TP53TSHRALDH1A1SRD5A2CA12 | |
| SCHEMBL15592626 | 0.79 | L3MBTL1 (0.44) | L3MBTL1EPHX2POLBALDH1A1KMT2A | |
| SCHEMBL2366245 | 0.79 | POLB (0.44) | TSHRL3MBTL1EPHX2POLBALDH1A1 | |
| SCHEMBL657937 | 0.79 | POLB (0.47) | L3MBTL1EPHX2POLBALDH1A1KMT2A | |
| SCHEMBL4004484 | 0.79 | KMT2A (0.45) | L3MBTL1EPHX2POLBALDH1A1KMT2A | |
| Lithium Ion SCHEMBL29771299 | 0.77 | POLB (0.42) | L3MBTL1EPHX2POLBALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL30612668 | 0.77 | L3MBTL1 (0.46) | L3MBTL1EPHX2POLBALDH1A1KMT2A | |
| SCHEMBL6918970 | 0.76 | L3MBTL1 (0.53) | L3MBTL1EPHX2POLBKMT2AMEN1 | |
| SCHEMBL4274064 | 0.76 | POLB (0.41) | L3MBTL1EPHX2POLBALDH1A1KMT2A | |
| SCHEMBL8619424 | 0.76 | NR4A2 (0.52) | TSHRL3MBTL1EPHX2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 380 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117126138-B | Compound for degrading target protein in ubiquitin-proteasome system, and preparation method and application thereof | 深圳湾实验室坪山生物医药研发转化中心 | 2026-05-22 | — | — | CN | claimed |
| CN-117126138-A | Compound for degrading target protein in ubiquitin-proteasome system, and preparation method and application thereof | 深圳湾实验室坪山生物医药研发转化中心 | 2023-11-28 | — | — | CN | claimed |
| EP-3596074-B1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2022-12-14 | — | — | EP | claimed |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | claimed |
| CN-109320513-A | A method of synthesis Trimetinib | 安庆奇创药业有限公司 | 2019-02-12 | — | — | CN | claimed |
| US-9328107-B2 | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | claimed |
| EP-2635567-B1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2015-10-28 | — | — | EP | claimed |
| CN-102924371-B | Preparation method of 6-oxo-1,6-dihydropyridine-3-carboxylic acid | UNIV NINGBO | 2015-05-13 | — | — | CN | claimed |
| EP-2018371-B1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2015-03-04 | — | — | EP | claimed |
| EP-2456763-B1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | claimed |
| EP-2663308-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | claimed |
| US-20130217702-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. | 2013-08-22 | — | — | US | claimed |
| CN-103201276-A | Indole derivatives | RICHTER GEDEON NYRT | 2013-07-10 | — | — | CN | claimed |
| CN-102924371-A | Preparation method of 6-oxo-1,6-dihydropyridine-3-carboxylic acid | UNIV NINGBO | 2013-02-13 | — | — | CN | claimed |
| US-20120270861-A1 | Primary Amines And Derivatives Thereof As Modulators Of The 5-HT2A Serotonin Receptor Useful For The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | claimed |
| EP-2483255-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-08-08 | — | — | EP | claimed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | claimed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | claimed |
| US-20090197935-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | claimed |
| US-4249009-A | Processes for preparing 2-chloro-5-trifluoromethylpyridine | REILLY TAR & CHEMICAL CORP. (US) | 1981-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217702-A1 | INDOLE DERIVATIVES | BDKRB1, BDKRB2, ARRB1 | TP53 3110/4885TSHR 1215/4885L3MBTL1 2457/4885 |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | TP53 4053/4885TSHR 101/4885L3MBTL1 4145/4885 |
| US-20120270861-A1 | Primary Amines And Derivatives Thereof As Modulators Of The 5-HT2A Serotonin Receptor Useful For The Treatment Of Disorders Related Thereto | HTR5A, HTR2A, HTR1A | TP53 4053/4885TSHR 101/4885L3MBTL1 4145/4885 |
| US-20090197935-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | TP53 4475/4885TSHR 73/4885L3MBTL1 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.